NEW YORK--(BUSINESS WIRE)--Cartesian Growth Corporation (“Cartesian”) (NASDAQ: GLBL), a publicly traded special purpose acquisition company, today announced the filing with the U.S. Securities and ...
Phase 3 trial of Descartes-08 in myasthenia gravis to start in 1H25 Cartesian Therapeutics has secured an agreement from the US Food and Drug Administration (FDA) under the Special Protocol Assessment ...
NEW YORK & ISTANBUL--(BUSINESS WIRE)--Cartesian Capital Group, a leading global private equity firm, announced today it has closed an equity investment in Turkey’s leading multi-brand food service ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback